Arcus Biosciences (NYSE: RCUS) insider transactions
In the twelve months to 10 November 2026, executives and directors of Arcus Biosciences reported 35 open-market sales of 434,039 shares ($10.5m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 21 August 2026 | Azoy Alexander | Chief Accounting Officer | Option exercise, 10b5-1 plan | +2,827 | $15.44 | 42,408 | Form 4 |
| 21 August 2026 | Azoy Alexander | Chief Accounting Officer | Open-market sale, 10b5-1 plan | −2,827 | $30.00 | 39,581 | Form 4 |
| 10 July 2026 | Jaen Juan C. | President | Open-market sale, 10b5-1 plan | −19,799 | $28.61 | 822,508 | Form 4 |
| 10 July 2026 | Jaen Juan C. | President | Open-market sale, 10b5-1 plan | −268 | $29.40 | 822,240 | Form 4 |
| 9 July 2026 | Jaen Juan C. | President | Open-market sale, 10b5-1 plan | −48,502 | $30.05 | 842,307 | Form 4 |
| 24 June 2026 | Jaen Juan C. | President | Open-market sale | −6,431 | $29.66 | 890,809 | Form 4 |
| 23 June 2026 | Jaen Juan C. | President | Open-market sale | −14,067 | $27.69 | 898,937 | Form 4 |
| 23 June 2026 | Jaen Juan C. | President | Open-market sale | −1,697 | $28.06 | 897,240 | Form 4 |
| 22 June 2026 | Jaen Juan C. | President | Open-market sale | −9,236 | $27.03 | 913,004 | Form 4 |
| 11 June 2026 | Perlman Andrew J | Director | Grant or award | +5,700 | — | 48,325 | Form 4 |
| 11 June 2026 | Falberg Kathryn E | Director | Grant or award | +5,700 | — | 44,300 | Form 4 |
| 11 June 2026 | Kaneko Yasunori | Director | Grant or award | +5,700 | — | 25,700 | Form 4 |
| 11 June 2026 | Machado Patrick | Director | Grant or award | +5,700 | — | 44,300 | Form 4 |
| 11 June 2026 | Lacey David L. | Director | Grant or award | +5,700 | — | 76,652 | Form 4 |
| 11 June 2026 | Lambert Nicole | Director | Grant or award | +5,700 | — | 43,000 | Form 4 |
| 11 June 2026 | Ribas Antoni | Director | Grant or award | +5,700 | — | 44,300 | Form 4 |
| 11 June 2026 | Tang Carolyn C. | General Counsel | Option exercise | +34,090 | $2.57 | 184,607 | Form 4 |
| 1 June 2026 | Azoy Alexander | Chief Accounting Officer | Open-market sale, 10b5-1 plan | −2,562 | $25.77 | 39,581 | Form 4 |
| 11 May 2026 | Goeltz II Robert C. | Chief Financial Officer | Open-market sale, 10b5-1 plan | −7,763 | $25.63 | 84,161 | Form 4 |
| 23 January 2026 | Rosen Terry J | Chief Executive Officer | Grant or award | +79,000 | — | 2,236,409 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Arcus Biosciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.